Strategy

Ligand-based targeting

Conventional chemotherapeutic agents do not preferentially localize at the site of disease, which may cause unnecessary toxicity and prevent escalation to therapeutic active regimens.

Philochem uses state-of-the-art technologies technologies to discover and develop novel therapeutics based on small organic ligands, cyclic peptides, and antibody fragments.

The approach crucially relies on the identification of accessible markers of disease and on the discovery of high affinity ligands, which facilitate pharmacodelivery applications. 

Philochem develops product candidates, validates them in relevant models of disease and moves the most promising agents to clinical trials. While most activity are focused on oncology, the potential of Philochem’s  approach extends to other disease areas, including chronic inflammation.

References

Zana et al,. (2022), Clin Cancer Res CCR-22-1788

–

Galbiati et al. (2022) J Nucl Med, numed.122.264036

–

Backhaus et al. (2021) Eur J Nucl Med Mol Imaging, 10.21203/rs.3.rs-969176/v1

–

Millul et al. (2021) PNAS, 118, 16, e2101852118

–

Cazzamalli et al. (2018) Clin Cancer Res, 24, 3656-67

–

Wichert et al. (2015) Nat Chem, 7, 241-9

–

Neri and Supuran (2011) Nat Rev Drug Discov, 10, 767-77

–

Neri and Bicknell (2005) Nat Rev Cancer, 5, 436-46